Sign inJoin waitlistJoin the waitlist

JN

Julie Nangia

Associate Professor · Baylor College of Medicine

Credentials: · · · · ·

History

Baylor College of Medicine
Present

Rush University Medical Center
2007–2009
University of Texas
2004–2007
University of Missouri–Kansas City School of Medicine
2000–2004

Research

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Journal of Clinical Oncology · 2019 · 299 citations
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial
JAMA · 2017 · First of 15 authors · 174 citations
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Clinical Cancer Research · 2020 · 135 citations

Mothaffar Rimawi
15 papers
AW
Antonio Wolff
10 papers
Anna Storniolo
7 papers
CP
Catherine Van Poznak
7 papers
IK
Ian Krop
7 papers
Nancy Lin
7 papers
Kent Osborne
6 papers
Rita Nanda
6 papers
Eric Winer
5 papers
Michelle Melisko
5 papers
Polly Niravath
5 papers
Rachel Freedman
5 papers

Clinical trials

Ruxolitinib for Premalignant Breast Disease
Principal investigator · Completed · Phase 2
Julie Nangia
2018–2024
Scalp Cooling to Prevent Chemo-induced Hair Loss
Principal investigator · Unknown
Julie Nangia
2014–2022
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033